Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve ...
“This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives,” ...
The shares of biotechnology firm Cytokinetics are approaching what may be one of the most consequential weeks in the company’s recent timeline. Investor attention is intensely focused on an imminent ...
The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve ...
An ABG test checks how well your lungs and kidneys work by measuring oxygen and carbon dioxide in your blood. This test helps doctors know if your body has an acid-base balance issue and if treatment ...
Background Little evidence is available about heart rate (HR) response to exercise as well as its relationship with functional capacity in amyloid cardiomyopathy. Then, in a multicentre cohort of ...
All candidate predictors were obtained from the first clinical assessment within 6 hours after admission (first available values), including vital signs, GCS score, arterial blood gas parameters (PaO2 ...
🤖 AI Chat - Generate scoring rules from natural language 📊 Visual Blocks - Blockly-based rule visualization Compound Conditions - Support for and / or logic 📐 Formula Support - BMI, GFR, and custom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback